Merck announced this weekend the results of a Phase 3 trial evaluating Keytruda as an adjuvant treatment for patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions.

In the third predefined interim analysis, Keytruda improved overall survival (OS) by 38% versus placebo. At 48 months, the estimated OS rate was 91.2% for Keytruda-treated patients, versus 86.0% for placebo-treated patients.

The OS benefit for Keytruda patients was observed in key subgroups, the aboratory points out.

According to Dr. Toni K. Choueiri, Director of the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Jerome and Nancy Kohlberg Professor of Medicine, Harvard Medical School, this is the first-ever Phase 3 trial to demonstrate improved survival in kidney cancer patients at risk of recurrence after surgery.

Copyright (c) 2024 CercleFinance.com. All rights reserved.